跳至主要内容
临床试验/ACTRN12622000981729
ACTRN12622000981729尚未招募未知

Refractory haEmorrhage Devices trial: a multi-arm, multi-stage, multicentre randomized active controlled superiority trial to evaluate the efficacy of uterine tamponade devices for the management of refractory postpartum haemorrhage

DP-UNFPA-UNICEF-WHO-WORLD BANK special programme of research, development and research training in human reproduction (HRP). World Health Organization0 个研究点目标入组 2,306 人开始时间: 2022年7月13日最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
2,306

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
16 Years 至 49 Years(—)
性别
Female

入选标准

  • Women will be eligible for the trial if they provide consent, have a vaginal birth and experience PPH likely to be caused by uterine atony, not responding to first-line treatment with uterotonic drugs, and therefore require further treatment to control the bleeding according to the birth attendant’s opinion. These criteria apply for both Stage 1 and Stage 2.

排除标准

  • Eligible women will not be randomized either if the clinical condition or the severity of the bleeding imply performing an invasive surgical procedure without delay at the judgment of the birth attendant in charge, or they present a clinical chorioamnionitis or in utero foetal death, they have been diagnosed with cervical cancer during pregnancy, have known uterine anomalies, or have allergy to trial device material . These criteria apply for both Stage 1 and Stage 2.

研究者

发起方
DP-UNFPA-UNICEF-WHO-WORLD BANK special programme of research, development and research training in human reproduction (HRP). World Health Organization

相似试验